What Happened? Shares of medical technology company Teleflex (NYSE:TFX) jumped 9.2% in the afternoon session after the company reported first-quarter 2026 fi...
Medical technology company Teleflex (NYSE:TFX) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 32.3% year on year to $54...
Medical technology company Teleflex (NYSE:TFX) will be reporting earnings this Thursday morning. Here’s what investors should know. Teleflex missed analysts’...
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Disclaimer: This content is intended for informational purposes only and is not financial advice. Today’s date is April 9, 2026. Introduction In the high-stakes arena of medical technology, few stories are as dramatic as the current transformation of Teleflex Incorporated (NYSE: TFX). Once a darling of the "growth-at-any-cost" era, the Wayne, Pennsylvania-based company found itself [...]
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
What Happened? Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.2% in the afternoon session after an activist shareholder urged the company ...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...
Over the last six months, Teleflex’s shares have sunk to $113.26, producing a disappointing 13% loss - a stark contrast to the S&P 500’s 4.8% gain. This was ...
What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the hea...
Medical technology company Teleflex (NYSE:TFX) missed Wall Street’s revenue expectations in Q4 CY2025, with sales falling 28.5% year on year to $569 million. Its non-GAAP profit of $1.93 per share was 48.4% below analysts’ consensus estimates.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
